To prevent visual impairment caused by choroidal neovascularization in patients with PXE, intravitreal injections of anti-VEGF compounds are now in routine use with considerable success [77,78]. This evidence concerns the gene VEGFA and pseudoxanthoma elasticum (inherited or acquired).